Ongoing change in the treatment of HIV-associated malignancies in the HAART era

Expert Review of Clinical Pharmacology

Volumn 2, Issue 3, 2009, Pages 283-293

  Malfitano, Antonello ^a   Barbaro, Giuseppe ^b   Barbarini, Giorgio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biotherapy; Chemotherapy; HAART; HIV; Lymphoma; Malignancy; Stem cell rescue

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PACLITAXEL; PHOTOFRIN; PREDNISOLONE; PREDNISONE; PROTEINASE INHIBITOR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRY SKIN; DYSPHAGIA; ELECTRON THERAPY; FACE EDEMA; FATIGUE; FIBROSIS; GERM CELL TUMOR; HAND FOOT SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IMMUNE RESPONSE; INCIDENCE; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHEDEMA; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHOTOALLERGY; PHOTODYNAMIC THERAPY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; REVIEW; SKIN DISEASE; SURVIVAL TIME; TREATMENT INDICATION; VOMITING;

EID: 70149094328     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.1     Document Type: Review

References (88)

1. International collaboration on HIV and cancer: highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst. 92, 1823-1830 (2000).
2. Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20, 1645-1654 (2006).
3. Selik RM, Byers RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J. Acquir. Immune Defic. Syndr. 29, 378-387 (2002).
4. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13, 2563-2570 (1999).
5. Portsmouth S, Stebbing J, Gill J et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 17, 17-22 (2003).
6. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Philips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. AIDS 10, 1101-1105 (1996).
7. Glesby MJ, Hoover DR, Weng S et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J. Infect. Dis. 173, 1477-1480 (1996).
8. Gressen EL, Rosenstock JG, Xie Y, Corn BW. Palliative treatment of epidemic Kaposi's sarcoma of the feet. Am. J. Clin. Oncol. 22, 286-290 (1999).
9. Evans MD, Yassa M, Podgorsak EB, Roman TN, Schreiner LJ, Souhami L. Surface applicators for high dose rate brachytherapy in AIDS-related Kaposi's sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 39, 769-774 (1999).
10. Bernstein ZP, Wilson BD, Oseroff AR et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS 13, 1697-1704 (1999).
11. Walmsley S, Northfeldt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J. Acquir. Immune Defic. Syndr. 22, 235-245 (1999).
12. Bodsworth NJ, Bloch M, Bower M, Donnel D, Yocum R. Phase III vehicle controlled, multicentered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am. J. Clin. Dermatol. 2, 77-87 (2001).
13. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13, 2105-2111 (1999).
14. Holkova B, Takeshita K, Cheng DM et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J. Clin. Oncol. 19, 3848-3851 (2001).
15. Laubenstein Lj, Krigel RL, Odajn YK CM et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J. Clin. Oncol. 2, 1115-1120 (1984).
16. Gill PS, Bernstein-Singer M, Espina BM et al. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. AIDS 6, 1477-1481 (1992).
17. Gill PS, Wernz J, Scadden DT et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14, 2353-2364 (1996).
18. Northfelt DW, Dezube BJ, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized Phase III clinical trial. J. Clin. Oncol. 16, 2445-2451 (1998).
19. Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. 16, 683-651 (1998).
20. Henry D, Cooley P, Volberding P. Final results of a Phase III randomized trial of doxil vs. daunoxome in patients with AIDS-related Kaposi's sarcoma (KS). Proc. Am. Soc. Clin. Oncol. 21, 411a (2002) (Abstract 1640).
21. Gill P, Hadienberg J, Espina B et al. Low dose paclitaxel (Taxol) every two weeks over three hours is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. Presented at: The American Society of Hematology (ASH), Thirty-Ninth Annual Meeting, Seattle, WA, USA 2-5 December (1995) (Abstract 1516).
22. Saville M, Lietzau J, Pluda J et al. Activity of paclitaxel (Taxol) as therapy for HIV-associated Kaposi's sarcoma. Lancet 346, 26-28 (1995).
23. Nasti G, Errante D, Talamini R et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a Phase II study. J. Clin. Oncol. 18, 1550-1557 (2000).
24. Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 18, 2593-2602 (2000).
25. Koon HB, Bubley GJ, Pantanowitz L et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 23, 982-989 (20059.
26. Cianfrocca M, Cooley T, Lee J et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma: a Phase I AIDS Malignancy Consortium study. J. Clin. Oncol. 20, 153-159 (2002).
27. Little RF, Pluda JM, Wyvill KM et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi's sarcoma. Blood 107, 4650-4657 (2006).
28. Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematol. Oncol. Clin. North Am. 10, 1111-1124 (1996).
29. Kaplan LD, Straus DJ, Testa MA et al. Low-dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 336, 1641-1648 (1997).
30. Sandler AS, Kaplan LD. Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV disease. Hematol. Oncol. Clin. North Am. 10, 1111-1124 (1996).
31. Gill P, Levine A, Krailo M et al. AIDS-related malignant lymphoma. Results of prospective treatment trials. J. Clin. Oncol. 5, 1322 (1987).
32. Kaplan LD, Abrams DI, Feigal E et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 261, 719-724 (1989).
33. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J. Clin. Oncol. 23, 4430-4438 (2005).
34. Weiss R, Mitrou P, Arasteh K et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial. Cancer 106, 1560-1568 (2006).
35. Navarro JT, Ribera JM, Oriol A et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxyl-doxorubicin, vincristine and prednisone. Br. J. Haematol. 112, 909-915 (2001).
36. Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non Hodgkin's lymphoma. Cancer 91, 155-163 (2001).
37. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15, 1483-1491 (2001).
38. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J. Clin. Oncol. 19, 2171-2178 (2001).
39. Vinodh R, Nannan P, Richard M et al. Paclitaxel in the treatment of immunodeficiency virus-1 associated Kaposi's sarcoma-drug - drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother. Pharm. 43, 516-519 (1999).
40. Fumagalli L, Zucchetri M, Parisi I et al. The pharmakokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother. Pharm. 45, 495-501 (2000).
41. Matthews GV, Bower M, Mandalia S et al. Changed in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 96, 2730-2734 (2002).
42. Sparano JA, Wiernik PH, HU X et al. Pilot trial of infusional cyclophosphsmide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated, non Hodgkin's lymphoma. J. Clin. Oncol. 14, 3026-3035 (1996).
43. Little RF, Pittaluga S, Grant N et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of an antiretroviral suspension and tumor biology. Blood 101, 4653-4654, (2003).
44. Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized Phase III trial of CHOP with or without rituximab in patients with HIV-associated, non Hodgkin's lymphoma. AIDS-malignancies consortium trial 010. Blood 106, 1538-1543 (2005).
45. Spina M, Jaeger U, Sparano JA et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated, non Hodgkin's lymphoma: pooled results from 3 Phase 2 trials. Blood 105, 1891-1897 (2005).
46. Boue F, Gabarre J, Gisselbrect G et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated, non Hbdgkin's lymphoma. J. Clin. Oncol. 24, 4123-4128 (2006).
47. Levine AM, Lee J, Kaplan L, Liebes LF, Sparano JA. Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034. J. Clin. Oncol. 26, (2008) (Abstract 8527).
48. Tirelli U, Errante D, Spina M et al. Second line chemotherapy in HIV-related non-Hodgkin's lymphoma. Cancer 77, 2127-2131 (1996).
49. Bi J, Espina B, Tulpule A et al. High-dose cytosine - arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphomas. J. Acquir. Defic. Syndr. 28, 416-421 (2001).
50. Philip T, Guglielmi C, Hagenbeck A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333, 1540-1545 (1995).
51. Krishnan A, Molina A, Zaia J et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 98, 3857-3859 (2001).
52. Mazhar D, Stebbing J, Lewis R, Nelson M, Gazzard BG, Bower M. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood 107, 3412-3414 (2006).
53. Wang ES, Straus DJ, Teruya-Feldstein J et al. Intensive chemotherapy with cyclophosphamide, doxotubicin, high-dose methotrexate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98, 1196-1205 (2003).
54. Cortes J, Thomas D, Rios A et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94, 1492-1499 (2002).
55. Appleby P, Beral V, Newton R et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst. 92, 1823-1830 (2000).
56. Baumgartner J, Rachlin J, Beckstead J et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J. Neurosurg. 73, 206-211 (1990).
57. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system in AIDS. Neurology 44, 147-1479 (1994).
58. Jacomet C, Girard P, Lebrette M et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 11, 1725-1730 (1997).
59. Appleby P, Beral V, Newton R et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst. 92, 1823-1830 (2000).
60. Robinson W. Invasive and preinvasive cervical neoplasia in human immunodeficiency virus-infected women. Semin. Oncol. 27, 463-470 (2000).
61. HeardI, Tassie J, Kazachkine M et al. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 16, 1799-1802 (2002).
62. Biggar R, Horm J, Goedert J et al. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am. J. Epidemiol. 126, 578 (1984).
63. Biggar R, Burnett W, Mikl J et al. Cancer among New York men at risk of acquired immunodeficiency syndrome. Int. J. Cancer 43, 979 (1989).
64. Hessol N, Katz M, Liu J et al. Increased incidence of Hodgkin's disease in homosexual men with HIV infection. Ann. Intern. Med. 117, 309 (1992).
65. Reynolds P, Saunders L, Layefsky M et al. The spectrum of acquired immunodeficiency syndrome (AIDS)-associated malignancies in San Francisco, 1980-1987. Am. J. Epidemiol. 37, 19 (1993).
66. Lyter D, Kingsley L, Rinaldo C et al. Malignancies in the Multicenter AIDS Cohort Study (MACS), 1894-1994. Presented at: The American Society of Clinical Oncology, Thirty-Second Annual Meeting. PA, USA, 18-21 May 1996.
67. Biggar Rj, Frisch M, Engels EA et al. The National AIDS - Cancer Match Registry. Abstracts of the Fourth International AIDS Malignancy Conference, May 16-18, 2000 Bethesda, MD, USA. J. Acquir. Immune Defic. Syndr. 23, A8 (2000) (Abstract §3).
68. Biggar RJ, Jaffe ES, Goedert JJ et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS: Blood 108, 3786-3791 (2006).
69. Gold J, Altaac D, Ree H et al. HIV-associated Hodgkin's disease: a clinical study of 18 cases and review of the literature. Am. J. Hematol. 36, 93 (1991).
70. Monfardini S, Tirelli U, Vaccher E et al. Hodgkin's disease in 63 intravenous drug users with human immunodeficiency virus. Ann. Oncol. 2(Suppl. 2), 201 (1991).
71. Spina M, Gabarre J, Rossi G et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 100, 1984-1988 (2002).
72. Hartmann P, Rehwald U, Salzberger B et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann. Oncol. 14, 1562-1569 (2003).
73. Gabarre J, Marcelin AG, Azar N et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus-related lymphoma: results and impact on HIV disease. Haematologica 89, 1100-1108 (2004).
74. Serrano D, Carrion R, Balsalobre P et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp. Hematol. 33, 487-494 (2005).
75. Krishnan A, Molina A, Zaja J et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105, 874-878 (2005).
76. Powles T, Bower M, Stamash J et al. Outcome of patients with HIV-related germ cell tumours: a case - control study. Br. J. Cancer 80, 1526-1530 (2004).
77. Bower M, Collins S, Cottril C et al; on behalf of the AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 9, 336-388 (2008).
78. Engels EA, Brock MV, Chen J et al. Elevated incidence of lung cancer among HIV-infected individuals. J. Clin. Oncol. 24, 1383-1388 (2006).
79. Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 17, 371-375 (2003).
80. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 15, 325-339 (1996).
81. Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and out come. HIV-HCC Cooperative Italian-Spanish Group. AIDS 18, 2285-2293 (2004).
82. Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J. Gastroenterol. 14, 1657-1663 (2008).
83. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J. Infect. Dis. 188, 1412-1429 (2003).
84. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Sem. Liver Dis. 26, 273-284 (2006).
85. Liu R, Paxton W, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
86. Wu L, Paxton WA, Kassam N et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681-1692 (1997).
87. Patel P, Hanson DL, Sullivan PS et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann. Intern, Med. 148, 728-736 (2008).
88. Crum-Cianflone N, Husiek KH, Marconi V et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23(1), 41-50 (2009).